Sold as Xopenex. Every FDA application for this active ingredient: 1 branded and 12 generic.
As of Nov 16, 2026, FDA lists 13 applications for Levalbuterol Hydrochloride (sold as Xopenex), first approved Mar 25, 1999, with 2 new uses approved and 0 published complete response letters.
| Levalbuterol HCl | Part D | $2.1M | +19% | 6,502 |
| Levalbuterol HCL | Part B | $704K | +49% | 21,039 |
| Levalbuterol Concentrate | Part D | $44K | -11% | 134 |
| Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationParoxysmal Atrial Fibrillation · China National Center for Cardiovascular Diseases | Not applicable | Recruiting | Oct 16, 2026 |
| Clearance in Primary Ciliary DyskinesiaPrimary Ciliary Dyskinesia, PCD · University of North Carolina, Chapel Hill | Not applicable | Not yet recruiting | Jul 13, 2026 |
| Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma ExacerbationsAsthma Acute, Asthma Attack · Oman Medical Speciality Board | Phase 2 | Recruiting | Aug 8, 2025 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension · Duke University | — | Recruiting | Feb 20, 2020 |
| Mar 25, 1999 | XopenexNDA 20837 · New dosage form | Hikma | 19 | Discontinued |
| Apr 9, 2008 | Levalbuterol HydrochlorideANDA 77756 | Impax Labs Inc | 1 | Marketed |
| Mar 20, 2009 | Levalbuterol HydrochlorideANDA 78309 | Mylan Speciality LP | 5 | Marketed |
| Mar 15, 2013 | Levalbuterol HydrochlorideANDA 77800 | Pharmobedient | 2 | Discontinued |
| Apr 26, 2013 | Levalbuterol HydrochlorideANDA 90297 | Teva Pharms USA | 4 | Marketed |
| Dec 13, 2013 | Levalbuterol HydrochlorideANDA 78171 | Cipla | 3 | Marketed |
| Sep 11, 2014 | Levalbuterol HydrochlorideANDA 200875 | Teva Parenteral | 4 | Marketed |
| Mar 22, 2016 | Levalbuterol HydrochlorideANDA 203653 | Ritedose Corp | 2 | Marketed |
| Dec 30, 2016 | Levalbuterol HydrochlorideANDA 207625 | Luoxin Aurovitas | 1 | Marketed |
| Jan 31, 2017 | Levalbuterol HydrochlorideANDA 207628 | Luoxin Aurovitas | 1 | Marketed |
| Nov 5, 2018 | Levalbuterol HydrochlorideANDA 207820 | Sun Pharm | 1 | Discontinued |
| Oct 21, 2024 | Levalbuterol HydrochlorideANDA 218770 | Mankind Pharma | 0 | Discontinued |
| May 26, 2026 | Levalbuterol HydrochlorideANDA 215217 | Nephron | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA